Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adcetris in Hodgkin lymphoma unsuitable for chemotherapy
NCT02567851Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- Feb 2014
- Primary completion
- Jan 2016
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brentuximab vedotin in classical Hodgkin lymphoma (cHL), sponsored by University of Birmingham. Started Feb 2014; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT02567851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02567851.